CIK 0001711279
- Large accelerated filer
Krystal Biotech, Inc.
Sign in to watch- Ticker
- KRYS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 821080209
- Phone
- +1 412-586-5830
- Business address
- 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203
- 4 Planned sale Chief Accounting Officer sold 53,428 shares at an average $101.60 ($5,428,115)
- 4 Planned sale Director sold 50,000 shares at $95.02 ($4,751,185)
- 4 Planned sale Director sold 17,100 shares at $90.74 ($1,551,579)
- 4 Planned sale Director sold 7,900 shares at $90.32 ($713,493)
- 4 Planned sale President, R&D sold 50,000 shares at an average $87.65 ($4,382,424)
- 4 Planned sale President and CEO sold 50,000 shares at an average $87.65 ($4,382,424)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 40,000 shares at $83.25 ($3,329,972)
- 4 Derivatives Options or other derivatives
- 4 Shares withheld for taxes Chief Accounting Officer gave up 2,144 shares (to pay taxes)
- 4 Shares withheld for taxes President, R&D gave up 3,057 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 4,350 shares (to pay taxes)
- 4 Open-market sale President, R&D sold 50,000 shares at an average $80.79 ($4,039,744)
- 4 Open-market sale President and CEO sold 50,000 shares at an average $80.79 ($4,039,744)
- 4 Open-market sale President, R&D sold 7,686 shares at an average $80.08 ($615,525)
- 4 Open-market sale President and CEO sold 7,686 shares at an average $80.08 ($615,525)
- 4 Open-market sale President, R&D sold 19,422 shares at an average $80.34 ($1,560,411)
- 4 Open-market sale President and CEO sold 19,422 shares at an average $80.34 ($1,560,411)
- 4 Open-market sale President, R&D sold 21,099 shares at an average $80.10 ($1,689,986)
Page 5 of 10 · 186 filings